Want to join the conversation?
$VRTX said the U.S. Food and Drug Administration (FDA) approved Orkambi for use in children with cystic fibrosis (CF) ages 6 through 11 who have two copies of the F508del mutation. In addition, $VRTX lowered guidance for 2016 Orkambi revenues to a range of $950-990MM.
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)
$AGIO plunge 15%.. what's happening... is this going for a toss !